English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  Although mutations in the promoter region of the telomerase reverse transcriptase ( TERT p) gene are the most common alterations in glioblastoma (GBM), their clinical significance remains unclear. Therefore, we investigated the impact of  TERT p status on patient outcome and clinicopathological features in patients with GBM over a long period of follow-up.    Methods  We retrospectively analyzed 153 cases of GBM. Six patients with isocitrate dehydrogenase 1 ( IDH1 ) or  H3F3A  gene mutations were excluded from this study. Among the 147 cases of  IDH  wild-type GBM, 92 (62.6%) had the  TERT p mutation. Clinical, immunohistochemical, and genetic factors ( BRAF ,  TP53  gene mutation, CD133, ATRX expression,  O  6 -methylguanine-DNA methyltransferase [ MGMT ] promoter methylation) and copy number alterations (CNAs) were investigated.    Results  GBM patients with the  TERT p mutation were older at first diagnosis versus those with  TERT p wild type (66.0 vs. 60.0 years, respectively,  P  = .034), and had shorter progression-free survival (7 vs. 10 months, respectively,  P  = .015) and overall survival (16 vs. 24 months, respectively,  P  = .017). Notably, magnetic resonance imaging performed showed that  TERT p-mutant GBM was strongly associated with multifocal/distant lesions ( P  = .004). According to the CNA analysis,  TERT p mutations were positively correlated with  EGFR  amp/gain,  CDKN2A  deletion, and  PTEN  deletion; however, these mutations were negatively correlated with  PDGFR  amp/gain,  CDK4  gain, and  TP53  deletion.    Conclusions    TERT p mutations were strongly correlated with multifocal/distant lesions and poor prognosis in patients with  IDH  wild-type GBM. Less aggressive GBM with  TERT p wild type may be a distinct clinical and molecular subtype of  IDH  wild-type GBM.

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma